Development of insulin-dependent diabetes mellitus in a patient with chronic hepatitis C during therapy with interferon-α

European Journal of Gastroenterology and Hepatology

Volumn 13, Issue 3, 2001, Pages 295-298

  Eibl, Nicole ^a   Gschwantler, Michael ^a   Ferenci, Peter ^a   Eibl, Martha M ^a   Weiss, Werner ^a   Schernthaner, Guntram ^a  

^a KRANKENANSTALT RUDOLFSTIFTUNG   (Austria)

Author keywords

Autoimmunity; Diabetes mellitus; Hepatitis C; Interferon; Keywords

Indexed keywords

RECOMBINANT ALPHA2B INTERFERON; RIBAVIRIN;

ADULT; ANTIBODY TITER; ARTICLE; CASE REPORT; DISEASE ASSOCIATION; DRUG SAFETY; HEPATITIS C; HLA TYPING; HUMAN; INSULIN DEPENDENT DIABETES MELLITUS; MALE; PRIORITY JOURNAL; RISK BENEFIT ANALYSIS;

ADULT; ANTIBODIES; ANTIVIRAL AGENTS; AUTOIMMUNITY; DIABETES MELLITUS, TYPE 1; GLUTAMATE DECARBOXYLASE; HEPATITIS C, CHRONIC; HUMANS; INTERFERON ALFA-2B; MALE; RIBAVIRIN; RISK;

EID: 0035102355     PISSN: 0954691X     EISSN: 14735687     Source Type: Journal    
DOI: 10.1097/00042737-200103000-00015     Document Type: Article

References (15)

1. Dusheiko G. Side effects of alpha interferon in chronic hepatitis C. Hepatology 1997; 26 (3 suppl 1): 112S -121S.
2. Miossec P. Cytokine-induced autoimmune disorders. Drug Safety 1997; 17: 93 -104.
3. Strebelow M, Schlosser M, Ziegler B, Rjasanowski J, Ziegler M. Karlsburg type-1 diabetes risk study of a general population: frequencies and interactions of the four major type-1 diabetes associated autoantibodies studied in 9419 schoolchildren. Diabetologia 1999; 42: 661 -670.
4. Koivisto VA. Interferon-alfa and development of type 1 diabetes mellitus. Lancet 1992; 340: 1236. 1236.
5. Fabris P, Betterle C, Floreani A, Greggio NA, de Lazzari F, Naccarato R. et al. Development of type 1 diabetes during interferon alpha therapy for chronic HCV hepatitis. Lancet 1992; 340: 1236. 1236.
6. Fabris P, Betterle C, Greggio NA, Zanchetto R, Bosi E, Biasin MR. Insulin-dependent diabetes mellitus during alpha interferon therapy for chronic viral hepatitis. J Hepatol 1998; 28: 514 -517.
7. Tohda G, Oida K, Higashi S, Hayasi T, Miyamori I. Interferon-α and development of type-1 diabetes [Observation]. Diabetes Care 1998; 21: 1774. 1774.
8. Waguri M, Hanafusa T, Itoh N. Antibodies to glutamic acid decarboxylase induced by interferon-alpha therapy for chronic viral hepatitis [Letter]. Diabetologia 1996; 39: 126. 126.
9. Shiba T, Morino Y, Tagawa K, Fujino H, Unuma F. Onset of diabetes with high titer anti-GAD antibody after IFN therapy for chronic hepatitis. Diabetes Res Clin Pract 1995; 30: 237 -241.
10. Ferenci P, Brunner H, Vogel W, Gschwantler M, Datz CH, Steindl-Munda P. Effect of initial interferon dosing and dose on response to combination therapy with ribavirin in chronic hepatitis C [Abstract]. Gastroenterology 1999; 116: A1299. A1299.
11. Chakrabarti D, Hultgren B, Stewart A. IFN-α induces autoimmune T cells through the induction of intercellular adhesion molecule-1 and B 7.: 2. J Immunol 1996; 157: 522 -528.
12. Foulis AK. Interferon-alpha and IDDM: comment. Diabetologia 1996; 39: 127. 127.
13. Steindl PE, Kutilek M, Novavek G. Interferon treatment of chronic hepatitis C frequently leads to a marked increase in serum triglycerides [Abstract]. Gastroenterology 1997; 112: A1389. A1389.
14. Caronia S, Taylor K, Pagliaro L, Carr C, Palazzo U, Petrik J. et al. Further evidence for an association between non-insulin-dependent diabetes mellitus and chronic hepatitis C virus infection. Hepatology 1999; 30: 1059 -1063.
15. McMurray RW, Elbourne K. Hepatitis C virus infection and autoimmunity. Semin Arthritis Rheum 1997; 26: 689 -701.